Dr Melinda Tan

MD, MMed(Int Med), MRCP(UK)

Consultant

Singapore General Hospital

Specialty: Haematology

Make an Appointment

About Doctor

Languages Spoken

Professional Appointments and Committee Memberships

Awards

Publications

Conditions Treated By This Doctor

Acute Lymphocytic Leukemia (ALL) Aplastic Anaemia Chronic Lymphocytic Leukemia (CLL) Chronic Myeloid Leukemia (CML) Deep Vein Thrombosis Essential Thrombocythemia and Myelofibrosis Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myelofibrosis Myeloma Polycythemia Vera Thalassaemia

Clinical Interests

Laboratory Haematology, Lymphoma, Myeloma

Clinical Appointments

Consultant

SingHealth Duke-NUS Blood Cancer Centre

Consultant

Haematology

Consultant

About Doctor

Dr Tan received her medical training at the Duke-NUS Medical School. She subsequently joined the department of Haematology as it provides her with the opportunity to treat a wide range of blood disorders, and marries the best of clinical and laboratory medicine. She has a special interest in multiple myeloma and flow cytometry.　

Languages Spoken

English

Professional Appointments and Committee Memberships

Clinical Tutor – Yong Loo Lin School of Medicine, NUS
Clinical Instructor – Duke-NUS Medical School

Awards

Singhealth Health Quality Service HERO awards 2021
Service Quality Award (Silver) 2019

Publications

Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143. Available from:
Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C. BCMA-targeting approaches for treatment of multiple myeloma. Panminerva Med [Internet]. 2021 Mar;63(1):28–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32955181
Jaya-Bodestyne SL, Lee LH, Tan LK, Tan KH, Østbye T, Malhotra R, et al. Risk factors for pregnancy-associated venous thromboembolism in Singapore. J Perinat Med [Internet]. 2021 Feb 23;49(2):153–8.
Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150.
Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C. Current and future perspectives of maintenance therapy in multiple myeloma. Panminerva Med [Internet]. 2020 Dec;62(4):225–33.
Jen W-Y, Yoong J, Liu X, Tan MSY, Chng WJ, Chee Y-L. Qualitative Study of Factors Affecting Patient, Caregiver and Physician Preferences for Treatment of Myeloma and Indolent Lymphoma. Patient Prefer Adherence [Internet]. 2020;14:301–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32109996
Chew M-H, Koh P-K, Tan M, Lim K-H, Carol L, Tang C-L. Mismatch repair deficiency screening via immunohistochemical staining in young Asians with colorectal cancers. World J Surg. 2013 Oct;37(10):2468–75.
Tan MSY, Narasimhalu K, Ong SYK. Letting the cat out of the bag: shifting practices of cancer disclosure in Singapore. Singapore Med J. 2012 May;53(5):344–8.